Galcanezumab

Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody against the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research[1].

Product Specifications

CAS Number

[1578199-75-3]

Product Name Alternative

LY 2951742

UNSPSC

12352203

Target

CGRP Receptor

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/galcanezumab.html

Purity

98.00

Solubility

H2O

Smiles

[Galcanezumab]

Molecular Weight

(145.5 kDa)

References & Citations

[1]Yvette N Lamb. Galcanezumab: First Global Approval. Drugs. 2018 Nov;78 (16) :1769-1775.|[2]Hashikawa-Hobara N, et al., Lack of alpha CGRP exacerbates the development of atherosclerosis in ApoE-knockout mice. Sci Rep. 2024 Aug 8;14 (1) :18377.|[3]Benschop RJ, et al., Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthritis Cartilage. 2014 Apr;22 (4) :578-85.